Biogen (BIIB) Capital Expenditures (2009 - 2026)

Biogen (BIIB) has reported Capital Expenditures for 18 consecutive years, with $51.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 38.01% year-over-year to $51.2 million; the TTM figure through Mar 2026 stood at $167.9 million (up 15.87% YoY), while the FY2025 annual figure was $153.8 million, changed 0.07% from the prior year.
• Capital Expenditures came in at $51.2 million for Q1 2026 at Biogen, up from $43.9 million in the prior quarter.
• The five-year high for Capital Expenditures was $86.4 million in Q4 2022, with the low at $26.6 million in Q2 2025.
• Average Capital Expenditures over 5 years is $51.5 million, with a median of $46.2 million recorded in 2025.
• Across the five-year window, Capital Expenditures surged 92.41% in 2023 and tumbled 52.83% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $86.4 million in 2022, then decreased by 24.54% to $65.2 million in 2023, then slumped by 39.72% to $39.3 million in 2024, then advanced by 11.7% to $43.9 million in 2025, then advanced by 16.63% to $51.2 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $51.2 million, $43.9 million, and $46.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.